Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

X
Trial Profile

A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RPESC-RPE-4W (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors Luxa Biotechnology
  • Most Recent Events

    • 26 Apr 2024 According to The California Institute for Regenerative Medicine media release, in Apr 2024, California Institute for Regernative Medicines (CIRM) awarded Luxa Biotechnology $US 4 million to advance clinical research of RPESC-derived RPE for dry age-related macular degeneration and awards will support three projects in the Agency's clinical program, including this Phase I/IIa Study program.
    • 20 Apr 2023 According to Luxa Biotechnology media release, this trial includes the Cedars Sinai Biomanufacturing Center, Emmes.
    • 20 Apr 2023 According to Luxa Biotechnology media release, update on trial progress will be provided at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top